Athersys (NASDAQ: ATHX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-08 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.100 | -0.090 | 0.0100 | ||||
REV | 690.000K | 2.912M | 2.222M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Athersys (NASDAQ: ATHX) through any online brokerage.
Other companies in Athersys’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Orchard Therapeutics (NASDAQ:ORTX), 89bio (NASDAQ:ETNB), Lumos Pharma (NASDAQ:LUMO) and Gemini Therapeutics (NASDAQ:GMTX).
The latest price target for Athersys (NASDAQ: ATHX) was reported by B of A Securities on Monday, May 23, 2022. The analyst firm set a price target for 0.25 expecting ATHX to rise to within 12 months (a possible 1.79% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Athersys (NASDAQ: ATHX) is $0.2456 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Athersys.
Athersys’s Q2 earnings are confirmed for Monday, August 8, 2022.
There is no upcoming split for Athersys.
Athersys is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.